Androgen and Androgen Receptor in Kidney Cancer

Crossmark: check for updates

Authors

  • Joshua Cho Departments of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
  • Kouji Izumi Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Sci- ence, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
  • Chiung-Kuei Huang Departments of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA; Assistant Professor, Department of Medicine and Pathology, Division of Gastroenterology and Liver Research, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 55 Claverick St. 4

DOI:

https://doi.org/10.17140/NPOJ-1-e003

Keywords:

malegender, carcinoma, renal sarcoma

Abstract

Kidney cancer is one of the top ten most common cancers in men and women. There
are four types of kidney cancer, including Renal Cell Carcinoma (RCC), Transitional cell
carcinoma, renal sarcoma, and Wilm’s tumor. The most common type of kidney cancers is
renal cell carcinoma (RCC), with around nine out of ten kidney cancers being RCC (American
Cancer Associate). Epidemiology studies have identified several risk factors associated with
kidney cancer.1 Among them, male gender is associated with twice incidence rate of RCC
as female.2
Androgen and Androgen Receptor (AR) are major factors contributing to malegender-associated-diseases, such as prostate cancer,3
suggesting that androgen and AR might
be involved in RCC development and progression

References

Moyad MA. Review of potential risk factors for kidney (renal cell) cancer. Seminars in urologic oncology. 2001; 19: 280-293

Chow WH, Dong LM, Devesa SS. Epidemiology and risk fac-tors for kidney cancer. Nature reviews. Urology. 2010; 7: 245- 257. doi: 10.1038/nrurol.2010.46

Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine reviews. 2004; 25: 276-308. doi: 10.1210/er.2002- 0032

Wagle DG, Murphy GP. Hormonal therapy in ad-vanced renal cell carcinoma. Cancer. 1971; 28: 318- 321. doi: 10.1002/1097-0142(197108)28:2<318::AID-CNCR2820280209>3.0.CO;2-D

Alberto P, Senn HJ. Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs. Cancer. 1974; 33: 1226-1229. doi: 10.1002/1097-0142(197405)33:5<1226::AID-CNCR2820330506>3.0.CO;2-Z

Bracci U, DiSilverio F, Concolino G. Hormonal therapy of renal cell carcinoma (rcc). Progress in clinical and biological research. 1982; 100: 623-640.

Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Seminars in oncology. 1983; 10: 422-430. Nephrol Open J

Poster DS, Bruno S, Penta JS, Pinna K, Vilk P, Macdonald JS. Current status of chemotherapy, hormonal therapy, and im-munotherapy in the treatment of renal cell carcinoma. American journal of clinical oncology. 1982; 5: 53-60.

Raghavaiah NV. Hormone treatment of advanced renal cell carcinoma. Urology. 1982; 19: 123-126. doi: 10.1016/0090- 4295(82)90563-5

Noh SJ, Kang MJ, Kim KM, et al. Acetylation status of p53 and the expression of dbc1, sirt1, and androgen recep-tor are associated with survival in clear cell renal cell carci-noma patients. Pathology. 2013; 45: 574-580. doi: 10.1097/ PAT.0b013e3283652c7a

Zhu G, Liang L, Li L, et al. The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology. 2014; 83: 510 e519-524. doi: 10.1016/j.urology.2013.10.022

Heinlein CA, Chang C. Androgen receptor (ar) coregulators: An overview. Endocrine reviews. 2002; 23: 175-200.

He D, Li L, Zhu G, et al. Asc-j9 suppresses renal cell carci-noma progression by targeting an androgen receptor-dependent hif2alpha/vegf signaling pathway. Cancer research. 2014; 74: 4420-4430. doi: 10.1158/0008-5472.CAN-13-2681 Page e8

Downloads

Published

2015-06-26

How to Cite

Joshua Cho, Kouji Izumi, & Chiung-Kuei Huang. (2015). Androgen and Androgen Receptor in Kidney Cancer. Nephrology, 1(2), 44–45. https://doi.org/10.17140/NPOJ-1-e003

Issue

Volume 1 Issue 2 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.